Cardiovascular disease is a leading cause of morbidity and mortality. Individuals with underlying cardiovascular disease are at high risk for adverse outcomes from influenza infections. Although additional studies are needed, current evidence suggests the influenza vaccine may reduce the risk of cardiovascular death and coronary events. In addition to their overall efforts to encourage influenza vaccination for all eligible persons, pharmacists should pay special attention to these high-risk individuals.
Get full access to this article
View all access options for this article.
References
1.
FihnSDGardinJMAbramsJ. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: A report of the American College of Cardiology Foundation/American Heart Association Task Force on, Practice Guidelines, and the American Collage of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol.2012;60:e44–164.
2.
GoASMozaffarianDRogerVL; on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2013 update: A report from the American Heart Association. Circulation. 2013;127:e6–e245. http://my.americanheart.org/statements. Accessed August 22, 2013.
3.
DavisMMTaubertKBeninAL. Influenza vaccination as secondary prevention for cardiovascular disease: A science advisory from the American Heart Association/American College of Cardiology. Circulation. 2006;114(14):1549–1553.
4.
GlezenWPDeckerMPerrottaDM. Survey of underlying conditions of persons hospitalized with acute respiratory disease during influenza epidemics in Houston, 1978-1981. Am Rev Respir Dis.1987;136(3):550–555.
5.
SmithSAPolandGA. Use of influenza and pneumococcal vaccines in people with diabetes. Diabetes Care. 2000;23:95–108.
6.
EickhoffTCShermanILSerflingRE. Observations on excess mortality associated with epidemic influenza. JAMA. 1961;176(9):776–782.
7.
HousworthJLangmuirAD. Excess mortality from epidemic influenza, 1957-1966. Am J Epidemiol. 1974;100(1):40–48.
8.
ReichertTASimonsenLSharmaA. Influenza and the winter increase in mortality in the United States, 1959-1999. Am J Epidemiol. 2004;160(5):492–502.
9.
Warren-GashCSmeethLHaywardAC. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: A systematic review. Lancet Infect Dis. 2009;9(10):601–610.
10.
LoombaRSAggarwalSShahPHAroraRR. Influenza vaccination and cardiovascular morbidity and mortality: Analysis of 292,383 patients. J Cardiovasc Pharmacol Ther.2012;17:277–283.
11.
JohnstoneJLoebMKoonTK. Influenza vaccination and major adverse vascular events in high-risk patients. Circulation. 2012;126:27–86.
12.
TeoKYusufSSleightP; ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: The Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (ONTARGET/TRANSCENT) trials. Am Heart J. 2004;148:52–61.
13.
ONTARGET Investigators, Yusuf S, Teo K, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–1559.
14.
TRANSCEND Investigators, Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomized controlled trial. Lancet. 2008;372:1174–1183.
15.
GurfinkelEPLeon de la FuenteRMendizOMautnerB.Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study. Eur Heart J. 2004;25:25–31.
16.
GurfinkelEPde la FuenteRL. Two-year follow-up of the FLU Vaccination Acute Coronary Syndromes (FLUVACS) registry. Tex Heart Inst J.2004;31:28–32.
17.
MacIntyreCRHeywoodAEKovoorP. Ischaemic heart disease, influenza and influenza vaccination: A prospective case control study [published online ahead of print August 22, 2013]. Heart. http://heart.bmj.com/search?fulltext=influenza&submit=yes&x=0&y=0. Accessed August 28, 2013.
18.
GurevichVSPleskovVMLevayaMV. Autoimmune nature of influenza atherogenicity. Ann N Y Acad Sci.2005;1050(27):410–416.
19.
Van LentenBJWagnerACNayakDP. High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection. Circulation.2001;103(18):2283–2288.
20.
Van LentenBJWagnerACAnantharamaiahGM. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation.2002;106(9):1127–1132.
21.
MadjidMNaghaviMLitovskySCasscellsSW. Influenza and cardiovascular disease: A new opportunity for prevention and the need for further studies. Circulation.2003;108(22):2730–2736.
22.
NaghaviMWydePLitovskyS. Influenza infection exerts prominent inflammatory and thrombotic effects on the atherosclerotic plaques of apolipoprotein E-deficient mice. Circulation.2003;107(5):762–768.
Centers for Disease Control and Prevention (CDC). Summary recommendations: Prevention and control of influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices—(ACIP)—United States, 2013-14. http://www.cdc.gov/flu/professionals/acip/2013-summary-recommendations.htm. Accessed August 25, 2013.
